Panavir - 37 reviews, instructions for use

Gel for external and local use

INSTRUCTIONS

on the use of the medicinal product herpes for medical use (herpes ointment, herpes preparation, ointment for papillomas)

PANAVIR®

REGISTRATION NUMBER: LS-001697.

TRADE NAME: PANAVIR ®.

GROUP NAME: Polysaccharides of Solanum tuberosum shoots.

DOSAGE FORM: Gel for external and local use.

COMPOSITION (PER 100 G):

active substance - Panavir ® (polysaccharides of Solanum tuberosum shoots) - 0.002 g;

excipients : glycerol - 30.00 g, macrogol 4000 - 15.00 g, macrogol 400 - 38.00 g, ethanol 95% - 1.00 g, sodium hydroxide - 0.40 g, lanthanum nitrate hexahydrate - 2.20 g, water - up to 100.00 g.

DESCRIPTION:

A homogeneous mass of white color with a weak specific odor.

PHARMACOTHERAPEUTIC GROUP:

Antiviral agent of plant origin.

ATX CODE: D06BB.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Panavir ® is a purified extract of shoots of the Solanum tuberosum plant; The main active ingredient is a hexose glycoside, consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.

The drug Panavir ® has a virusostatic effect. Active against herpes simplex viruses types I and II. Suppresses the replication and polymerase reactions of viruses, blocking the synthesis of viral DNA in affected skin cells and/or mucous membranes.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, no negative effects on reproductive function and fetal development were established.

Pharmacokinetics

The pharmacokinetics of this dosage form of the drug has not been studied.

INDICATIONS FOR USE

Infectious and inflammatory diseases of the skin and/or mucous membranes caused by the herpes simplex virus types I and II (including genital herpes).

Human papillomavirus infection of the skin and/or mucous membranes of the genitals and perianal area in combination with laser destruction of genital warts.

CONTRAINDICATIONS

Individual intolerance and hypersensitivity to the components of the drug.

Children under 18 years of age.

USE IN PREGNANCY AND BREASTFEEDING

Use during pregnancy is only possible if the expected benefit to the mother outweighs the potential risk to the fetus.

If it is necessary to use the drug during lactation, breastfeeding should be stopped while taking the drug.

METHOD OF APPLICATION AND DOSES

Externally and locally.

The gel (herpes ointment) is applied in a thin layer to the affected areas of the skin and/or mucous membranes 5 times a day.

For the treatment of infectious and inflammatory diseases of the skin and/or mucous membranes caused by the herpes simplex virus types I and II (including genital herpes) - 5 times a day for 4-5 days. The course of treatment can be extended up to 10 days.

For the treatment of human papillomavirus infection - 2 times a day for 5 days before and 10 days after laser destruction of condylomas.

SIDE EFFECT

Rapid redness and itching of the skin and/or mucous membranes may occur in the area where the gel is applied.

If you notice any other side effects not listed in the instructions, tell your doctor.

OVERDOSE

No cases of overdose have been registered. The results of preclinical studies indicate low toxicity of the drug.

INTERACTIONS WITH OTHER MEDICINES

Not registered.

SPECIAL INSTRUCTIONS

It is recommended to start treatment at the earliest possible stage of the disease, at the first signs (itching, tingling, redness, feeling of tension), in this case the development of the vesicular stage of the disease can be completely prevented.

The drug herpes Panavir ® is not intended for use in ophthalmology. When applying the gel to the face, avoid getting it into the eyes.

INFLUENCE ON THE ABILITY TO DRIVE VEHICLES AND MECHANISMS

There is no data on the possibility of a negative effect of the drug on the ability to drive vehicles and carry out potentially hazardous activities that require special attention and speed of psychomotor reactions.

RELEASE FORM

Gel for external and local use 0.002%.

3 g, 5 g, 10 g or 30 g in an aluminum tube with an internal varnish coating.

1 tube along with instructions for use in a cardboard pack.

STORAGE CONDITIONS

In a dry place, protected from light, at a temperature of 2 to 25 ° C.

Keep out of the reach of children.

BEST BEFORE DATE

3 years.

Do not use after the expiration date stated on the packaging.

VACATION CONDITIONS

Available without a prescription.

OWNER OF REGISTRATION CERTIFICATES

LLC "National Research Green Oak", Russia, 141800 Moscow region, Dmitrov, st. Professional, no. 151.

Key words - ointment for herpes, herpes preparations, ointment for papillomas, treatment of papillomas

Reviews about Panavir, questions, doctor's comments

Ekaterina asks: 2022-01-12 16:43:09
Will Panavir help if I accidentally scratched off a scab from herpes?

Anastasia asks: 2021-12-20 11:50:57

Is it possible to use this gel to cure papellomas in intimate places?

Zar asks: 2021-11-01 22:39:58

I can't find it in the pharmacy,

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. on the website apteka.ru e-apteka.

Alena asks: 2021-08-31 16:14:12

Hello, can you please tell me how to apply Panavir gel after removing papillomas?

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. Panavir gel is applied both before removal, in order to reduce inflammatory reactions and the affected area, and after removal, in order to prevent relapse, reduce the viral load, improve recovery and wound healing. Thank you.

Nadezhda asks: 2021-08-11 07:32:15

Is it possible to give Panavir to a one-month-old baby?

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. Spray Inlight without additives, subbucally (behind the cheek). Small children are strictly forbidden to “squirt” down their throats. Thank you

Olga asks: 2021-06-11 17:28:40

Hello, tell me, can I use gel ointment during the first trimester?

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. The gel can be used during pregnancy in consultation with your doctor, when the risks from non-treatment are high. Thank you.

Tatyana asks: 2021-04-26 21:23:50

Is it possible to use the gel to treat papilloma on the box?

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. Can. Thank you.

Elena asks: 2021-04-11 21:27:34

Can the drug be used during pregnancy (3rd trimester)

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. You can use ampoules, sprays. The use of the gel is under the supervision of a physician.

Elena asks:2021-04-11 14:01:11

Can the drug be used during pregnancy (3rd trimester)

Korobkova Elena Vladimirovna Obstetrician-gynecologist answers: Good afternoon. Available in ampoule and spray forms. Gel form - under the supervision of a doctor. Thank you.

Panavir, 5 pcs., 200 mcg, rectal suppositories

Solution for intravenous administration

jet slowly. The therapeutic dose of the drug is 200 mcg of active substance (contents of 1 amp. or 1 vial).

For the treatment of herpes virus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of gastric and duodenal ulcers in the acute phase and symptomatic ulcers of the gastroduodenal zone, 5 IV injections are used every other day for 10 days.

For the treatment of rheumatoid arthritis in combination with herpesvirus infection in immunocompromised patients, 5 IV injections are used with an interval of 24–48 hours; if necessary, the course can be repeated after 2 months.

For the treatment of ARVI and influenza, 2 IV injections are used with an interval of 18–24 hours.

For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used with an interval of 48 hours.

Use in pediatrics

: Panavir® is prescribed to children over 12 years of age at a dose of 100 mcg IV once a day. For the treatment of herpes virus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month. For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

Gel for external and local use

Externally and locally

. The gel is applied in a thin layer to the affected areas of the skin and/or mucous membranes 5 times a day. Duration of treatment is 4–5 days. The course of treatment can be extended up to 10 days.

Rectal suppositories

Rectally.

For the treatment of herpes virus infections and tick-borne encephalitis, use 1 supp. twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and human papillomavirus infections, 1 supp. three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of ARVI and influenza, 1 supp. at 24 hour intervals for 5 days.

Vaginal suppositories

Intravaginally.

Insert into the vagina in the evening, as deep as possible, in a supine position with slightly bent legs, 1 vag daily for 5 days. supp. A repeated course of treatment is possible after consulting a doctor.

Panavir, 5 pcs., 5 ml, 0.04 mg/ml, solution for intravenous administration

Solution for intravenous administration

jet slowly. The therapeutic dose of the drug is 200 mcg of active substance (contents of 1 amp. or 1 vial).

For the treatment of herpes virus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of gastric and duodenal ulcers in the acute phase and symptomatic ulcers of the gastroduodenal zone, 5 IV injections are used every other day for 10 days.

For the treatment of ARVI and influenza, 2 IV injections are used with an interval of 18–24 hours.

For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used with an interval of 48 hours.

Use in pediatrics

Gel for external and local use

Externally and locally

Rectal suppositories

Rectally.

For the treatment of herpes virus infections and tick-borne encephalitis, use 1 supp. twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of ARVI and influenza, 1 supp. at 24 hour intervals for 5 days.

Vaginal suppositories

Intravaginally.

Experience with the use of the drug Panavir in the treatment of anogenital warts

Bulay A.A., Erashova T.Yu., Suslov V.S.

UZ "MOKVD", Mogilev, Belarus

Objective: To evaluate the effectiveness and safety of the drug Panavir in patients with anogenital warts.

Materials and methods: Twenty-five patients diagnosed with anogenital warts (23 women and 2 men, average age 28.5 years) according to the clinical trial design received the drug Panavir 0.004%-5ml intravenously in bolus No. 5 (the first three injections were administered at intervals of 48 hours, two subsequent injections with an interval of 72 hours). Before treatment, the patients were examined by a therapist and a gynecologist (urologist), and the necessary laboratory tests were performed (general blood and urine tests, biochemical and immunological blood tests). In all patients, the presence of human papillomavirus was confirmed by PCR. The effectiveness of therapy was monitored after 1, 3 and 6 months. The following were assessed: tolerability of the drug, result after treatment.

Results: Two patients (8%) experienced side effects, which included low-grade fever, nausea and headache. These symptoms disappeared after completion of treatment.

During follow-up after 1 month, 5 patients (20%) completely disappeared from clinical manifestations. In 19 patients (76%), regression of condylomas (decrease in size) was observed. One (4%) had no dynamics of the clinical picture. After 3 months, 10 patients (40%) showed recovery, and the remaining 15 patients (60%) showed regression of the rash.

After 6 months of observation, the clinical picture of anogenital warts completely disappeared in 20 patients (80%). Four patients (16%) experienced further regression of the rash, and another one had a recurrence of the rash.

In control studies using PCR, 23 patients (92%) received a negative result. One patient with a clinical relapse had a positive laboratory result, and another patient without clinical manifestations also had a positive result.

When the immune status was re-determined, 6 out of 7 patients who had abnormalities in the immune status showed normalization and in one patient an improvement.

Conclusions: Panavir is an effective drug for the treatment of patients with anogenital warts, as evidenced by the absence of clinical manifestations and negative HPV PCR in 92% of cases. In the vast majority (92%) Panavir is well tolerated by patients. It should also be noted the positive immunomodulatory effect of the drug Panavir.

‹ Experience in the use of ozone therapy in the treatment of acne Up Experience in the use of the three-component external treatment complex “System 4” for the treatment of seborrhea and seborrheic dermatitis pilosist ›